Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;477(2):431-444.
doi: 10.1007/s11010-021-04283-2. Epub 2021 Nov 16.

Effect of intravenous cell therapy in rats with old myocardial infarction

Affiliations

Effect of intravenous cell therapy in rats with old myocardial infarction

Xian-Liang Tang et al. Mol Cell Biochem. 2022 Feb.

Abstract

Mounting evidence shows that cell therapy provides therapeutic benefits in experimental and clinical settings of chronic heart failure. However, direct cardiac delivery of cells via transendocardial injection is logistically complex, expensive, entails risks, and is not amenable to multiple dosing. Intravenous administration would be a more convenient and clinically applicable route for cell therapy. Thus, we determined whether intravenous infusion of three widely used cell types improves left ventricular (LV) function and structure and compared their efficacy. Rats with a 30-day-old myocardial infarction (MI) received intravenous infusion of vehicle (PBS) or 1 of 3 types of cells: bone marrow mesenchymal stromal cells (MSCs), cardiac mesenchymal cells (CMCs), and c-kit-positive cardiac cells (CPCs), at a dose of 12 × 106 cells. Rats were followed for 35 days after treatment to determine LV functional status by serial echocardiography and hemodynamic studies. Blood samples were collected for Hemavet analysis to determine inflammatory cell profile. LV ejection fraction (EF) dropped ≥ 20 points in all hearts at 30 days after MI and deteriorated further at 35-day follow-up in the vehicle-treated group. In contrast, deterioration of EF was halted in rats that received MSCs and attenuated in those that received CMCs or CPCs. None of the 3 types of cells significantly altered scar size, myocardial content of collagen or CD45-positive cells, or Hemavet profile. This study demonstrates that a single intravenous administration of 3 types of cells in rats with chronic ischemic cardiomyopathy is effective in attenuating the progressive deterioration in LV function. The extent of LV functional improvement was greatest with CPCs, intermediate with CMCs, and least with MSCs.

Keywords: Cell therapy; Fibrosis; Inflammation; Intravenous; Ischemic cardiomyopathy; Myocardial infarction; Repair; Stem cells.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare that they have no conflict of interest to disclose.

Figures

Fig. 1
Fig. 1
A Experimental protocol. Echo, echocardiogram; PBS, Dulbecco’s phosphate-buffered saline; MSCs bone marrow-derived mesenchymal stromal cells, CMCs cardiac mesenchymal cells, CPCs c-kit-positive cardiac cells, Pre-Rx pretreatment (30 days after MI)
Fig. 2
Fig. 2
Echocardiographic assessment of LV function. Bar graph illustrating LV EF (A), FAC (C), ESV (E), and SV (G) at baseline (BSL), before treatment (Pre-Rx) (i.e., 30 days after MI), and 35 days after the treatment (Post-Rx). △ change (absolute units) in echocardiographic parameters at 35 days after treatment (Post-Rx) vs. pretreatment values (Pre-Rx): EF ejection fraction (B), FAC fractional area change (D), ESV end-systolic volume (F), and SV stroke volume (H). Data are means±SEM
Fig. 3
Fig. 3
Hemodynamic assessment of LV function. Hemodynamic studies were performed with a Millar conductance catheter at 35 days after treatment, just before euthanasia. Quantitative analysis of hemodynamic variables: LV end-diastolic pressure (A), stroke volume (B), stroke work (C), dP/dt (D), ejection fraction (E), dP/dtmaxEDV (F), end-systolic elastance (G), and tau_weiss (H). Data are means±SEM
Fig. 4
Fig. 4
Morphometric analysis (A) and myocardial collagen content (B). A Quantitative analysis of LV morphometric parameters. The risk region comprises both the border zones and the scarred region. B Quantitative analysis of polarized light microscopic images showing total collagen content as a percent of the risk and noninfarcted regions. Data are means±SEM
Fig. 5
Fig. 5
Myocardial content of CD45-positive cells. Quantitative analysis of CD45-positive cells was performed in the risk (border and infarcted region) and noninfarcted regions of the LV sections. Values are mean±SEM
Fig. 6
Fig. 6
Hemavet analysis of inflammatory cells in the blood. Shown are WBCs, neutrophils (Ne), lymphocytes (Ly), the Ne/Ly ratio, and the platelet/Ly ratio at baseline (before cell infusion [0 day]), and 48 h (2 days) and 35 days (35 days) after intravenous infusion of vehicle (solid circles, n = 7), MSCs (solid squares, n = 11), CMCs (solid upward triangles, n = 5), or CPCs (solid inverted triangles, n = 7). Dots represent individual animals and bars represent means

Similar articles

Cited by

References

    1. Bolli R, Solankhi M, Tang XL, Kahlon A (2021) Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovasc Res. 10.1093/cvr/cvab135 - DOI - PMC - PubMed
    1. Bolli R, Tang XL, Guo Y, Li Q (2021) After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease. Can J Physiol Pharmacol 99:129–139. 10.1139/cjpp-2020-0406 - DOI - PMC - PubMed
    1. Wysoczynski M, Khan A, Bolli R (2018) New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res 123:138–158. 10.1161/circresaha.118.313251 - DOI - PMC - PubMed
    1. Li Q, Guo Y, Ou Q, Chen N, Wu WJ, Yuan F, O’Brien E, Wang T, Luo L, Hunt GN, Zhu X, Bolli R (2011) Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. Basic Res Cardiol 106:849–864. 10.1007/s00395-011-0180-1 - DOI - PMC - PubMed
    1. Hong KU, Guo Y, Li QH, Cao P, Al-Maqtari T, Vajravelu BN, Du J, Book MJ, Zhu X, Nong Y, Bhatnagar A, Bolli R (2014) c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS ONE 9:e96725. 10.1371/journal.pone.0096725 - DOI - PMC - PubMed